Abstract:Background Acute kidney injury (AKI) is often iatrogenic and potentially preventable. Reduced renal nicotinamide adenine dinucleotide (NAD(+)) is reported to increase the susceptibility of AKI. The present study explored the predictive value of urinary de novo NAD(+) synthetic metabolites for AKI using two independent cohorts. Methods The expression of de novo NAD(+) synthetic enzymes in human kidney was examined by immunohistochemistry and single-cell transcriptomes. Urine samples were collected from two independent cohorts: the methotrexate (MTX) cohort with high-dose MTX treatment for lymphoma (n = 189) and the liver transplantation cohort with orthotopic liver transplantation (n = 49). Urinary metabolomics study of NAD(+)de novo synthesis was performed by liquid chromatography with mass spectrometry, screening for AKI predictive biomarkers. Nephroseq database and immunohistochemistry were used to analyze kidney de novo NAD(+) synthetic enzymes expression in AKI-susceptible conditions. Results Human proximal tubule was the main structure in the kidney that expressed the necessary enzymes for NAD(+)de novo synthesis. In the MTX cohort, the urinary quinolinic acid (QA)/3-hydroxyanthranilic acid (3-OH AA) ratio before chemotherapy was significantly lower in those who developed AKI after chemotherapy compared with those who did not. This finding was consistent in the liver transplantation cohort. The area under the receiver-operating characteristic curve (AUC) of urinary QA/3-OH AA for AKI prediction was 0.749 and 0.729 in two cohorts, respectively. 3-Hydroxyanthranilic acid dioxygenase (HAAO), the enzyme catalyzing QA synthesis from 3-OH AA, decreased in AKI-susceptible diabetic kidneys. Conclusions The human proximal tubules were important source of NAD(+) from the de novo pathway. Reduced urinary QA/3-OH AA ratio, which possibly suggested decreased HAAO activity, could be a potential AKI predictive biomarker. Lay Summary Acute kidney injury (AKI) is a great threat to public health with a very high mortality in the intensive care unit setting. Strong evidence indicates that susceptibility to AKI differs significantly following an acute insult, and aging is a risk factor for AKI. However, the biological mechanism underlying this AKI susceptibility remains poorly understood, which hinders the development of biomarkers and interventional targets for AKI prevention. The present study characterized the de novo nicotinamide adenine dinucleotide (NAD(+)) metabolism in human kidney and explored the potential of using their metabolites in the urine to predict the development of AKI using two independent patient cohorts. We found that the urinary quinolinic acid/3-hydroxyanthranilic acid ratio had an ability to predict AKI with an AUC of 0.749 and 0.729 in these two cohorts, respectively. The present study provides valuable information not only on potential biomarkers that predict AKI but also potential intervention target to prevent AKI.

Derangement in Nicotinamide Adenine Dinucleotide Metabolism is Observed During Acute Kidney Injury Among Male Agricultural Workers at Risk for Mesoamerican Nephropathy

Derangement in nicotinamide adenine dinucleotide (NAD+) metabolism is observed during acute kidney injury among male agricultural workers at risk for Mesoamerican Nephropathy

Acute Kidney Injury in Sugarcane Workers at Risk for Mesoamerican Nephropathy

The Metabolites of De Novo NAD+ Synthesis Are a Valuable Predictor of Acute Kidney Injury.

Impaired Nicotinamide Adenine Dinucleotide Biosynthesis in the Kidney of Chronic Kidney Disease

Nicotinamide riboside: A promising therapy for MI-induced acute kidney injury by upregulating nicotinamide phosphoribosyltransferase-mediated NAD levels

Cell stress response impairs de novo NAD+ biosynthesis in the kidney

Nicotinamide riboside activates renal metabolism and protects the kidney in a model of Alport syndrome

NAD activates renal metabolism and protects from chronic kidney disease in a model of Alport syndrome

Changes in kidney function among Nicaraguan sugarcane workers

NAD+ precursor supplementation prevents mtRNA/RIG-I-dependent inflammation during kidney injury

Nicotinamide Attenuates the Progression of Renal Failure in a Mouse Model of Adenine-Induced Chronic Kidney Disease

Kinetics of the De Novo NAD/NADH Pathway from AKI to CKD

The significance of NAD + metabolites and nicotinamide N-methyltransferase in chronic kidney disease

Unraveling the nexus of NAD+ metabolism and diabetic kidney disease: insights from murine models and human data

Nicotinamide Mononucleotide Attenuates Renal Interstitial Fibrosis after AKI by Suppressing Tubular DNA Damage and Senescence

NAD metabolism modulates inflammation and mitochondria function in diabetic kidney disease

Renal Mitochondria Exhibit Cell Type-Specific Heterogeneity and Are Functionally Dynamic

Pre-emptive Short-term Nicotinamide Mononucleotide Treatment in a Mouse Model of Diabetic Nephropathy

Association Between Acute Kidney Injury Hospital Visits and Environmental Heat Stress at a Nicaraguan Sugarcane Plantation

Dysregulated nicotinamide adenine dinucleotide metabolome in patients hospitalized with COVID‐19